IL-2 is a powerful growth factor for T cells. New work shows that immune checkpoint blockade depends upon the presence of IL-2, and that mesenchymal stem cells can be efficiently engineered

to safely deliver it directly in advanced tumours to rescue CD8+ T cell responsiveness to anti-PD-L1 antibody treatment. Access through your institution Buy or subscribe This is a preview of

subscription content, access via your institution ACCESS OPTIONS Access through your institution Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value

online-access subscription $29.99 / 30 days cancel any time Learn more Subscribe to this journal Receive 12 print issues and online access $209.00 per year only $17.42 per issue Learn more

(2017). Article  CAS  Google Scholar  * Ross, S. H. & Cantrell, D. A. _Annu. Rev. Immunol._ 36, 411–433 (2018). Article  CAS  Google Scholar  * Rosenberg, S. A. _J. Immunol._ 192,

5451–5458 (2014). Article  CAS  Google Scholar  * Bae, J. et al. _Nat. Cell Biol_. https://doi.org/10.1038/s41556-022-01024-5 (2022). * Andreatta, M. et al. _Nat. Commun._ 12, 2965 (2021).

Article  CAS  Google Scholar  * Mo, F. et al. _Nature_ 597, 544–548 (2021). Article  CAS  Google Scholar  * Sun, Z. et al. _Nat. Commun._ 10, 3874 (2019). Article  CAS  Google Scholar  *

Levin, A. M. et al. _Nature_ 484, 529–533 (2012). Article  CAS  Google Scholar  * Mott, H. R. et al. _J. Mol. Biol._ 247, 979–994 (1995). Article  CAS  Google Scholar  * Westerman, K. A.

& Leboulch, P. _Proc. Natl Acad. Sci. USA_ 93, 8971–8976 (1996). Article  CAS  Google Scholar  * Li, X. et al. _Nat. Commun._ 10, 3251 (2019). Article  Google Scholar  * Miller, B. C. et

al. _Nat. Immunol._ 20, 326–336 (2019). Article  CAS  Google Scholar  * Guo, Y. et al. _Nat. Immunol._ 22, 746–756 (2021). Article  CAS  Google Scholar  * Krishna, S. et al. _Science_ 370,

1328–1334 (2020). Article  CAS  Google Scholar  * Herrera, F. G. et al. _Cancer Discov._ 12, 108–133 (2022). Article  CAS  Google Scholar  Download references AUTHOR INFORMATION AUTHORS AND

AFFILIATIONS * Department of Oncology, Ludwig Institute for Cancer Research Lausanne, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland Melita Irving, Yaquelin

Ortiz-Miranda & George Coukos Authors * Melita Irving View author publications You can also search for this author inPubMed Google Scholar * Yaquelin Ortiz-Miranda View author

publications You can also search for this author inPubMed Google Scholar * George Coukos View author publications You can also search for this author inPubMed Google Scholar CORRESPONDING

AUTHOR Correspondence to George Coukos. ETHICS DECLARATIONS COMPETING INTERESTS G.C. has received grants or research support from, or is coinvestigator in clinical trials by, Bristol-Myers

Squibb, Celgene, Boehringer Ingelheim, Roche, Tigen Pharma, Iovance and Kite. The Lausanne University Hospital (CHUV) has received honoraria for advisory services G.C. has provided to

AstraZeneca AG, Bristol-Myers Squibb SA, F. Hoffmann-La Roche AG, MSD Merck AG and Geneos Therapeutics. G.C. has patents in the domain of antibodies and vaccines targeting the tumour

vasculature as well as technologies related to T cell expansion and engineering for T cell therapy. G.C. has received royalties from the University of Pennsylvania. The three co-authors are

included in an intellectual property filing regarding an IL-2 variant. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Irving, M., Ortiz-Miranda, Y.

& Coukos, G. IL-2 engineered MSCs rescue T cells in tumours. _Nat Cell Biol_ 24, 1689–1691 (2022). https://doi.org/10.1038/s41556-022-01029-0 Download citation * Published: 06 December

2022 * Issue Date: December 2022 * DOI: https://doi.org/10.1038/s41556-022-01029-0 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get

shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative